drugset / Trial / NCT01834885

A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD

NCT01834885

Phase 3 Withdrawn Novartis Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

Study is to show that QVA149 is superior to the standard of care, fluticasone/salmeterol, in patients with moderate to severe airflow limitation

Timeline

Start
2013-12
Primary completion
2014-09
Completion
2014-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Fluticasone Other / unclassified Inhaled
Subject QVA149 Other / unclassified Inhaled
Comparator Salmeterol Other / unclassified Inhaled